225 related articles for article (PubMed ID: 35737856)
1. Baseline characteristics and secondary medication adherence among Medicare patients diagnosed with transthyretin amyloid cardiomyopathy and/or receiving tafamidis prescriptions: A retrospective analysis of a Medicare cohort.
Roy A; Peterson A; Marchant N; Alvir J; Bhambri R; Bredl Z; Benjumea D; Kemner J; Parasuraman B
J Manag Care Spec Pharm; 2022 Jul; 28(7):766-777. PubMed ID: 35737856
[No Abstract] [Full Text] [Related]
2. Baseline Characteristics and Secondary Medication Adherence Patterns Among Patients Receiving Tafamidis Prescriptions: A Retrospective Analysis Using a National Specialty Pharmacy Dispensing Database.
Roy A; Peterson A; Marchant N; Alvir J; Bhambri R; Lynn J; Benjumea D; Prasad S; O'Brien A; Chen Y; Kemner J; Parasuraman B
Patient Prefer Adherence; 2022; 16():1115-1129. PubMed ID: 35517043
[TBL] [Abstract][Full Text] [Related]
3. Tafamidis medication adherence and persistence in patients with transthyretin amyloid cardiomyopathy in Japan.
Kato T; Ines M; Minamisawa M; Benjumea D; Keohane D; Alvir J; Kim R; Chen Y; Peixoto T; Kent M; Wogen J; Ishii T; Crowley A; Sugino T; Izumiya Y
ESC Heart Fail; 2024 May; ():. PubMed ID: 38783561
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Survival With Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy.
Elliott P; Drachman BM; Gottlieb SS; Hoffman JE; Hummel SL; Lenihan DJ; Ebede B; Gundapaneni B; Li B; Sultan MB; Shah SJ
Circ Heart Fail; 2022 Jan; 15(1):e008193. PubMed ID: 34923848
[TBL] [Abstract][Full Text] [Related]
5. Predictors of Nonadherence to Topical Intraocular Pressure Reduction Medications Among Medicare Members: A Claims-Based Retrospective Cohort Study.
Sheer R; Bunniran S; Uribe C; Fiscella RG; Patel VD; Chandwani HS
J Manag Care Spec Pharm; 2016 Jul; 22(7):808-817a. PubMed ID: 27348282
[TBL] [Abstract][Full Text] [Related]
6. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
Shah SJ; Fine N; Garcia-Pavia P; Klein AL; Fernandes F; Weissman NJ; Maurer MS; Boman K; Gundapaneni B; Sultan MB; Elliott P
JAMA Cardiol; 2024 Jan; 9(1):25-34. PubMed ID: 37966817
[TBL] [Abstract][Full Text] [Related]
7. Is the Currently Used Prescription Adjudication Date a Good Proxy for Calculating Medication Refill Adherence?
Lester CA; Look KA; Chui MA
J Manag Care Spec Pharm; 2016 Nov; 22(11):1311-1317. PubMed ID: 27783554
[TBL] [Abstract][Full Text] [Related]
8. Association of Tafamidis With Health Status in Patients With ATTR Cardiac Amyloidosis: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial.
Sperry BW; Hanna M; Maurer MS; Nativi-Nicolau J; Floden L; Stewart M; Wyrwich KW; Barsdorf AI; Kapadia H; Spertus JA
JAMA Cardiol; 2023 Mar; 8(3):275-280. PubMed ID: 36723935
[TBL] [Abstract][Full Text] [Related]
9. The Influence of a Community Pharmacy Automatic Prescription Refill Program on Medicare Part D Adherence Metrics.
Lester CA; Mott DA; Chui MA
J Manag Care Spec Pharm; 2016 Jul; 22(7):801-7. PubMed ID: 27348281
[TBL] [Abstract][Full Text] [Related]
10. Patterns of Adherence to Oral Atypical Antipsychotics Among Patients Diagnosed with Schizophrenia.
MacEwan JP; Forma FM; Shafrin J; Hatch A; Lakdawalla DN; Lindenmayer JP
J Manag Care Spec Pharm; 2016 Nov; 22(11):1349-1361. PubMed ID: 27783548
[TBL] [Abstract][Full Text] [Related]
11. A Multichannel Medication Adherence Intervention Influences Patient and Prescriber Behavior.
Leslie RS; Gilmer T; Natarajan L; Hovell M
J Manag Care Spec Pharm; 2016 May; 22(5):526-38. PubMed ID: 27123914
[TBL] [Abstract][Full Text] [Related]
12. Tafamidis 61 mg Patient Characteristics and Persistency? A Retrospective Analysis of German Statutory Health Insurance Data (IQVIA™ LRx).
Attal S; Kemner J; Alvir J; Barth S; Schuessler S
Cardiol Ther; 2024 Jun; 13(2):369-378. PubMed ID: 38615093
[TBL] [Abstract][Full Text] [Related]
13. Health impact of tafamidis in transthyretin amyloid cardiomyopathy patients: an analysis from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and the open-label long-term extension studies.
Rozenbaum MH; Garcia A; Grima D; Tran D; Bhambri R; Stewart M; Li B; Heeg B; Postma M; Masri A
Eur Heart J Qual Care Clin Outcomes; 2022 Aug; 8(5):529-538. PubMed ID: 33895806
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy.
Kazi DS; Bellows BK; Baron SJ; Shen C; Cohen DJ; Spertus JA; Yeh RW; Arnold SV; Sperry BW; Maurer MS; Shah SJ
Circulation; 2020 Apr; 141(15):1214-1224. PubMed ID: 32078382
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Tafamidis in Patients With Hereditary and Wild-Type Transthyretin Amyloid Cardiomyopathy: Further Analyses From ATTR-ACT.
Rapezzi C; Elliott P; Damy T; Nativi-Nicolau J; Berk JL; Velazquez EJ; Boman K; Gundapaneni B; Patterson TA; Schwartz JH; Sultan MB; Maurer MS
JACC Heart Fail; 2021 Feb; 9(2):115-123. PubMed ID: 33309574
[TBL] [Abstract][Full Text] [Related]
16. Association between dispensing channel and medication adherence among medicare beneficiaries taking medications to treat diabetes, high blood pressure, or high blood cholesterol.
Iyengar RN; Balagere DS; Henderson RR; LeFrancois AL; Rabbitt RM; Frazee SG
J Manag Care Spec Pharm; 2014 Aug; 20(8):851-61. PubMed ID: 25062079
[TBL] [Abstract][Full Text] [Related]
17. Causes of Cardiovascular Hospitalization and Death in Patients With Transthyretin Amyloid Cardiomyopathy (from the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial [ATTR-ACT]).
Miller AB; Januzzi JL; O'Neill BJ; Gundapaneni B; Patterson TA; Sultan MB; López-Sendón J
Am J Cardiol; 2021 Jun; 148():146-150. PubMed ID: 33667442
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT) and long-term extension study.
Damy T; Garcia-Pavia P; Hanna M; Judge DP; Merlini G; Gundapaneni B; Patterson TA; Riley S; Schwartz JH; Sultan MB; Witteles R
Eur J Heart Fail; 2021 Feb; 23(2):277-285. PubMed ID: 33070419
[TBL] [Abstract][Full Text] [Related]
19. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
[No Abstract] [Full Text] [Related]
20. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Maurer MS; Schwartz JH; Gundapaneni B; Elliott PM; Merlini G; Waddington-Cruz M; Kristen AV; Grogan M; Witteles R; Damy T; Drachman BM; Shah SJ; Hanna M; Judge DP; Barsdorf AI; Huber P; Patterson TA; Riley S; Schumacher J; Stewart M; Sultan MB; Rapezzi C;
N Engl J Med; 2018 Sep; 379(11):1007-1016. PubMed ID: 30145929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]